Skip Navigation LinksHome > August 2012 - Volume 54 - Issue 8 > Imputing At-Work Productivity Loss Using Results of a Random...
Journal of Occupational & Environmental Medicine:
doi: 10.1097/JOM.0b013e31825f31a1
Original Articles

Imputing At-Work Productivity Loss Using Results of a Randomized Controlled Trial Comparing Tapentadol Extended Release and Oxycodone Controlled Release for Osteoarthritis Pain

Lerner, Debra MS, PhD; Chang, Hong PhD; Rogers, William H. PhD; Benson, Carmela MS; Chow, Wing PharmD, MPH; Kim, Myoung S. PhD, MA, MBA; Biondi, David DO

Continued Medical Education
Collapse Box


Objective: To determine the impact of tapentadol extended release (ER) versus placebo or oxycodone controlled release (CR) on the work productivity of adults with chronic moderate to severe knee osteoarthritis pain.

Methods: Using clinical trial data on pain outcomes, a validated methodology imputed treatment group differences in at-work productivity and associated differences in productivity costs (assuming a $100,000 annual salary per participant).

Results: Imputed improvements in at-work productivity were significantly greater for tapentadol ER compared with either placebo (mean, 1.96% vs 1.51%; P = 0.001) or oxycodone CR (mean, 1.96% vs 1.40%; P < 0.001). Mean net savings per participant were $450 (P < 0.01) for tapentadol ER versus placebo and $560 (P = 0.001) for tapentadol ER versus oxycodone CR.

Conclusion: Effective osteoarthritis pain treatment also may help employees to function better at work and reduce their employers' productivity costs.

©2012The American College of Occupational and Environmental Medicine


Article Tools


Article Level Metrics